Levels of anti-insulin antibodies in diabetic retinopathy patients: an observational cross-sectional study.

IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Future Science OA Pub Date : 2024-05-15 eCollection Date: 2024-01-01 DOI:10.2144/fsoa-2024-0002

Bismark N Mohammed, Emmanuel K Ofori, Christian N Adekena, Seth K Amponsah, Henry Asare-Anane, Seth D Amanquah, Mubarak Abdul-Rahman, Kwesi N Amissah-Arthur

引用次数: 0

Abstract

Aim: This study evaluated the levels of anti-insulin antibodies (AIAs) and the influence of some antidiabetic medications on AIA in diabetes mellitus (DM) patients with retinopathy. Patient & methods: An observational cross-sectional study. Results: A lower titer of AIA IgG was observed in the diabetic retinopathy (DR) and DM-only study categories compared with the control group [DR = 86 (5-560), DM-only = 50 (5-500), versus control = 200 (7-565); p = 0.017]. Taking nifedipine and metformin were negatively correlated (r = -0.32, p = 0.04) with the levels of AIA IgE in the DR group. Conclusion: A decreased titer of circulating AIAs was observed in the DR study category, suggesting that AIA may not contribute to the pathogenesis of DR.

查看原文本刊更多论文

糖尿病视网膜病变患者的抗胰岛素抗体水平：一项观察性横断面研究。

目的：本研究评估了患有视网膜病变的糖尿病（DM）患者的抗胰岛素抗体（AIAs）水平以及一些抗糖尿病药物对 AIAs 的影响。患者和方法：观察性横断面研究。研究结果与对照组相比，糖尿病视网膜病变（DR）和纯DM研究组的AIA IgG滴度较低[DR = 86 (5-560)，纯DM = 50 (5-500)，对照组 = 200 (7-565)；P = 0.017]。服用硝苯地平和二甲双胍与 DR 组的 AIA IgE 水平呈负相关（r = -0.32，p = 0.04）。结论在 DR 研究组中观察到循环 AIA 滴度降低，这表明 AIA 可能与 DR 的发病机制无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Science OA MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

5.00

自引率

4.00%

发文量

审稿时长

13 weeks

期刊介绍： Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries